Particularly noteworthy, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) revealed that IL-1β inhibition with the neutralizing antibody canakinumab decreases both the incidence and mortality of lung cancer in patients with atherosclerosis co-morbidities13. Here, IL1B is linked to lung cancer.